---
title: "Psilocybin (COMP360) in Treatment-resistant depression: COMP005"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: COMP005. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 74 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/comp005"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: COMP005

<a id="heading-3.1.1"></a>

## 3.1.1 COMP005

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Primary aim: single dose of COMP360 25 mg versus placebo with psychological support

> “Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)”
> “In this study, the primary aim is to assess the efficacy and safety of a single dose of COMP360 25 mg versus placebo for reducing symptom severity in TRD, when administered with psychological support.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.1-2"></a>

#### Secondary aims: durability, long-term safety, and retreatment

> “Durability of efficacy and long-term safety, and the efficacy and safety of re-treatment will be assessed in a 20-week single-dose, double-blind re-treatment part (Part B), and a 26-week open-label treatment part (Part C).”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “We believe that this design will enable us to appropriately characterize the efficacy, safety and durability of COMP360 administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates in the registry record

| Milestone | Registry entry |
| --- | --- |
| Study start (actual) | “2023-01-24” |
| Primary completion (actual) | “2025-05-28” |
| Study completion (actual) | “2026-04-15” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.2-2"></a>

#### Number of sites: registry and Form 10-K

> “This study has 40 locations”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “The first pivotal trial, COMP005, is a randomized, double-blind, placebo-controlled study, with 258 dosed participants across 40 trial sites in the United States”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.2-3"></a>

#### Number of sites: June 2025 Form 8-K

> “The ongoing COMP005 trial is a randomized, double-blinded, placebo-controlled study, which has dosed 258 participants with moderate-to-severe depression across 32 sites in the United States”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="topic-3.1.1.2-4"></a>

#### Timing of Part A completion

> “Part A, which concluded during the second quarter of 2025, and was blinded through 6 weeks”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Phase 3 randomized, double-blind, placebo-controlled, parallel-group design

> “This is a phase III, international, multi-centre, randomised, parallel group, fixed single-dose, double-blind, placebo-controlled study.”
> “The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week Screening Period.”
> “Part A will include a six-week follow-up from initial investigational product (IP) administration.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

| Design element | Registry entry |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.3-2"></a>

#### Parts A, B, and C as described in the 52-week release

> “In Part A, blinded through Week 6, eligible participants were randomized (2:1) to receive a single dose of 25 mg of COMP360 or placebo”
> “In Part B, blinded from Weeks 6 to 26, eligible participants could receive an additional dose of the same treatment to which they were originally randomized”
> “In Part C, open-label from Week 26 to 52, eligible participants from both dosing arms could receive a single dose of 25 mg”
> “There was a potential for a total of 3 doses of COMP360 across a 52-week period.”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.3-3"></a>

#### Retreatment criteria in Parts B and C

> “In Part B (20 weeks), participants could receive a second administration if they did not achieve remission at Week 6 or subsequently met criteria for relapse.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

> “During Part B, based on pre-specified criteria, participants were eligible either for a second administration of the treatment to which they were randomized or to resume antidepressants.”
> “Participants who complete part B and go into Part C during which participants who meet criteria for re-treatment may receive a 25mg dose of COMP360 psilocybin.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Concomitant antidepressants permitted after Part A

> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Timing of the 26-week data disclosure

> “Compass Pathways anticipates sharing 26-week data for COMP005 once all participants in the COMP006 trial have completed part A of the COMP006 trial.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Population described by the company

> “Adults with TRD (2-4 inadequate prior treatment responses) were randomized 2:1 to single administration of COMP360 25 mg or placebo in Part A (6 weeks).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.4-2"></a>

#### Key inclusion criteria

> “Aged ≥18 years at Screening”
> “Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition”
> “If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening”
> “MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression”
> “TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ.”
> “At Screening, agreement to discontinue all prohibited medications.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.4-3"></a>

#### Key psychiatric exclusion criteria

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.4-4"></a>

#### Exclusions for prior neuromodulation, psychotherapy, and psilocybin exposure

> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”
> “Transcranial magnetic stimulation within the past six months prior to Screening”
> “Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening”
> “Exposure to COMP360 psilocybin therapy prior to Screening”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Study arms

| Arm | Registry description |
| --- | --- |
| Experimental | “25 mg COMP360 Psilocybin” |
| Placebo comparator | “Matched placebo” |
| Intervention | “COMP360 Psilocybin administered under supportive conditions” |

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.5-2"></a>

#### Dosing by study part

> “Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

> “In Part B, participants who complete Part A will be followed for 20 weeks and those who meet criteria for re-treatment will have the option to receive an additional treatment dose according to their assigned dose.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

#### Psychological support and monitoring model in the trials

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “Patients wear eye shades to help them focus internally, lie on a bed, and listen to a carefully curated music playlist through a high-quality sound system and earphones.”
> “In our clinical trials, healthcare professionals refrain from intervening with the patient’s experience, unless required for safety reasons.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint as defined by the sponsor

> “The primary endpoint is the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “COMP360 25 mg versus placebo for the change from baseline in MADRS total score”
> “Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.6.1-2"></a>

##### Key secondary endpoint: Sheehan Disability Scale at Week 6

> “COMP360 25 mg versus placebo for the change from baseline in SDS total score”
> “Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.6.1-3"></a>

##### Development and validation of the MADRS

> “The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.”
> “The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.1.6.1-4"></a>

##### FDA guidance on primary and secondary endpoints in MDD trials

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”
> “Secondary endpoints assess other domains of symptom improvement relevant for labeling.”
> “Sheehan Disability Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.1.6.1-5"></a>

##### FDA guidance on the timing of the primary endpoint and durability

> “Thus, we consider 6 to 8 weeks an appropriate study”
> “Efficacy generally should be demonstrated within 1 week for a rapid-acting”
> “Durability of effect beyond the initial response should be characterized.”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.1.6.1-6"></a>

##### European Medicines Agency guidance on rating scales

> “Acceptable scales to determine symptomatic improvement include the Hamilton Rating Scale of Depression (HDRS), preferably the 17-item scale, and the Montgomery-Asberg Depression Rating Scale (MADRS), however other validated scales might be acceptable as well.”
> “For rapid acting antidepressants it is anticipated that specific scales, other than the most commonly used MADRS, will be developed and validated, in order to be able to fully capture the rapid onset of effect.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in TRD

> “In Study 1, the primary efficacy measure was change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of the 4-week double-blind induction phase. The MADRS is a ten-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe depression.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-3.1.1.6.1-8"></a>

##### Outcomes named in the ICER draft scope

> “Depressive symptom improvement (e.g., Montgomery–Åsberg Depression Rating Scale [MADRS])”
> “Rate of response, remission, and relapse”
> “Improvements in functional outcomes (e.g., Sheehan Disability Scale [SDS])”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-3.1.1.6.1-9"></a>

##### Minimal clinically important difference on the MADRS

> “To identify the minimal clinically important difference (MCID) for the Montgomery-Asberg Depression Rating Scale (MADRS) in randomised studies of depression, and to cross-validate the estimated MCID.”
> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.1.6.1-10"></a>

##### Clinically meaningful change on the MADRS and SDS in TRD

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”
> “The relationships between the CGI‐S and the MADRS, SDS and PHQ‐9 were established in a moderately severe TRD population and may not be generalizable to severely ill subjects.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

<a id="topic-3.1.1.6.1-11"></a>

##### Clinical meaning of MADRS response and remission thresholds

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”
> “If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “No consensus has emerged regarding an appropriate cutoff for defining remission on the Montgomery-Asberg Depression Rating Scale (MADRS).”
> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

<a id="topic-3.1.1.6.1-12"></a>

##### Response and remission definitions used by the company

> “Responder: ≥50% decrease in total score from baseline”
> “Remitter: ≤12 MADRS total score and no single item ≥4”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Clinically meaningful reduction in MADRS defined as a >25% reduction from baseline in MADRS total score at Week 6. This graph is a post hoc analysis.”
> “Remitters (n=11) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=31) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=115) = % CFB in MADRS ≤ 25%”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment

> “Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo.”

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)

<a id="topic-3.1.1.7.1-2"></a>

##### Participants dosed in Part A

> “The ongoing COMP005 trial is a randomized, double-blind, placebo-controlled study, with 258 dosed participants across the United States and is assessing the efficacy and safety of a single dose of 25 mg COMP360 versus placebo for reducing symptom severity in TRD (COMP360 25 mg: n=171; placebo: n=87).”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “A total of 258 participants received COMP360 (n=171) or placebo (n=87) in Part A.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants analyzed at Week 6 in the 25 mg arm

> “Total n at 6 weeks = 157 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants dosed in open-label Part C

> “Response/remission rates based on the 142 participants (n=90 from 25mg arm, n=52 from original Placebo arm) who received a 25mg dose in Part C.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Safety analysis set

> “N=number of participants in the treatment group in the Safety Analysis Set by administration; n = number of participants; TEAE = treatment emergent adverse event”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Efficacy analyses by study part

> “Least square mean in Part A. Observed mean in Part B and C”
> “No statistical analyses performed after the primary analysis at Week 6”
> “COMP 005 Part B (post Week 6) and COMP 006 Part B (post Week 9) results are based on observed data only (CFB Mean ± 95% CI).”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Descriptive statistics for MADRS change were assessed through Week 26.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.7.2-3"></a>

##### Post hoc responder analysis and Part C percentages

> “This graph is a post hoc analysis. Total n at 6 weeks = 157 (based on ITT)”
> “Percentages are based on the number of observed participants at the visit”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Randomized and dosed participants

> “A total of 258 participants received COMP360 (n=171) or placebo (n=87) in Part A.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.1-2"></a>

##### Participants in the 25 mg arm at Week 6

> “Total n at 6 weeks = 157 (8% dropout)”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.1-3"></a>

##### Second administration in Part B

> “Second dosing occurred in 70% (COMP360) and 53% (placebo).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.1-4"></a>

##### Entry into and dosing in open-label Part C

> “Approximately 70% of the study participants continued beyond Week 26 and entered Part C”
> “25 mg Arm: Approximately 80% (n=90) who entered Part C received an additional open-label dose; this was their second or third dose depending on whether they received an additional dose in Part B”
> “Placebo Arm: Approximately 90% (n=52) who entered Part C received an open-label 25 mg dose; this was their first dose of COMP360 25 mg given they received placebo in parts A and B”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “118 participants from 25mg arm entered Part C and 113 of those met eligibility criteria for open-label treatment of which 90 (80%) were dosed”
> “61 participants from Placebo arm entered Part C and 58 of those met eligibility criteria for open-label treatment of which 52 (90%) were dosed”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographics

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Female, n (%) | “93 (54.4)” | “47 (54.0)” |
| White, n (%) | “149 (87.1)” | “78 (89.7)” |
| Asian, n (%) | “11 (6.4)” | “4 (4.6)” |
| Black or African American, n (%) | “6 (3.5)” | “2 (2.3)” |
| American Indian or Alaska Native, n (%) | “0” | “1 (1.1)” |
| Other race, n (%) | “5 (2.9)” | “2 (2.3)” |
| Age, years, mean (SD) | “45.9 (13.4)” | “45.3 (14.4)” |
| Age, years, minimum and maximum | “19, 77” | “22, 72” |
| Age ≥65 years, n (%) | “15 (8.8)” | “11 (12.6)” |
| Prior psilocybin experience, n (%) | “5 (2.9)” | “5 (5.7)” |
| Prior psychedelic experience including psilocybin, n (%) | “8 (4.7)” | “6 (6.9)” |
| BMI, kg/m2, mean (SD) | “28.4 (6.2)” | “27.7 (6.1)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Treatment history and baseline MADRS

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Failed treatments in current episode: 1, n (%) | “2 (1.2)” | “1 (1.1)” |
| Failed treatments in current episode: 2, n (%) | “114 (66.7)” | “62 (71.3)” |
| Failed treatments in current episode: 3, n (%) | “45 (26.3)” | “19 (21.8)” |
| Failed treatments in current episode: 4, n (%) | “10 (5.8)” | “4 (4.6)” |
| Failed treatments in current episode: 5, n (%) | “0” | “1 (1.1)” |
| Treatments withdrawn in screening: 0, n (%) | “58 (33.9)” | “26 (29.9)” |
| Treatments withdrawn in screening: 1, n (%) | “38 (22.2)” | “32 (36.8)” |
| Treatments withdrawn in screening: 2, n (%) | “50 (29.2)” | “21 (24.1)” |
| Treatments withdrawn in screening: more than 2, n (%) | “25 (14.6)” | “8 (9.2)” |
| MADRS total score at baseline, mean (SD) | “31.5 (5.5)” | “31.5 (5.9)” |
| Mild (11-19), n (%) | “1 (0.6)” | “2 (2.3)” |
| Moderate (20-30), n (%) | “73 (42.7)” | “33 (37.9)” |
| Severe (≥31), n (%) | “97 (56.7)” | “52 (59.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Depression diagnosis history

| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
| --- | --- | --- |
| Length of current episode, months, mean (SD) | “34.1 (29.1)” | “38.6 (33.0)” |
| Current episode less than 1 year, n (%) | “30 (17.5)” | “20 (23.0)” |
| Current episode 1-2 years, n (%) | “52 (30.4)” | “19 (21.8)” |
| Current episode more than 2 years, n (%) | “89 (52.0)” | “48 (55.2)” |
| Lifetime depressive episodes, mean (SD) | “7.7 (10.9)” | “7.2 (7.6)” |
| Lifetime episodes 2-5, n (%) | “107 (62.6)” | “54 (62.1)” |
| Lifetime episodes 6-10, n (%) | “40 (23.4)” | “21 (24.1)” |
| Lifetime episodes more than 10, n (%) | “23 (13.5)” | “12 (13.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Part A: primary endpoint, change in MADRS total score at Week 6

> “A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with a p-value of p<0.001 and a clinically meaningful difference of -3.6 in change at the primary endpoint.”
> “Efficacy Data (MADRS): Single dose of COMP360 25 mg versus placebo with a mean treatment difference of -3.6 points, 95% CI[ -5.7, -1.5]; p<0.001”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “In COMP005, COMP360 25 mg significantly reduced MADRS scores versus placebo at Week 6 (LSMD: -3.6; 95% CI: -5.7, -1.5;”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.1.8.3-2"></a>

##### Part A: least squares mean differences in MADRS by visit

| Visit | COMP360 25 mg vs placebo, LS mean difference (95% CI), p-value |
| --- | --- |
| Day 2 | “-4.7 (-7.0, -2.3), p<0.001” |
| Week 1 | “-7.2 (-9.6, -4.8), p<0.001” |
| Week 3 | “-5.2 (-7.4, -2.9), p<0.001” |
| Week 6 (primary) | “-3.6 (-5.7, -1.5), p<0.001” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Statistical significance at all timepoints beginning the day after administration (Day 2) demonstrates rapid onset of action”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-3"></a>

##### Part A: post hoc analysis of participants with at least 25% MADRS reduction at Week 6

> “For participants who had a clinically meaningful reduction in MADRS (≥ 25%), a statistically significant rapid onset from the day following administration was maintained at all measured timepoints through Week 6 in the 25 mg arm”
> “25% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6 with durability lasting out through 26 weeks after just one or two doses of 25 mg”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Remitters (n=11) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=31) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=115) = % CFB in MADRS ≤ 25%”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-4"></a>

##### Part B: blinded follow-up and retreatment through Week 26

> “During Part B, numerical separation from placebo was maintained through Week 26.”
> “Reductions in MADRS total scores following one or two administrations of COMP360 25 mg were observed to be rapid and sustained for at least 26 weeks.”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

> “Through the randomized and blinded Part B up to week 26, the results show that there was a consistent separation between 25 mg of COMP360 and placebo.”
> “During Part B, 70% of participants in the 25mg arm and 53% of participants in the placebo arm received a second administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.8.3-5"></a>

##### Part B: remission after a second dose among Week 6 responders who had not remitted

> “Over 40% of those who achieved a clinically meaningful reduction in MADRS but had not remitted by 6 weeks went into remission after the second dose in Part B”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.1.8.3-6"></a>

##### Part C: open-label 25 mg dose in participants originally randomized to 25 mg

> “Notable additional benefit observed at all Part C timepoints through Week 52, with additional meaningful reduction in MADRS beyond what had been observed in Parts A and B, with an average 13-point reduction from baseline at Week 52”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Additional benefit observed after another Part C dose, for those in the 25mg arm, with average 13-point MADRS reduction from baseline at Week 52”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.3-7"></a>

##### Part C: first 25 mg dose in participants originally randomized to placebo

> “Meaningful average reduction of 10 points from baseline in MADRS at end of Part C from one dose”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.8.3-8"></a>

##### Part C: response and remission after the open-label 25 mg dose

> “40%-45% response rates (Responder: ≥50% decrease in total score from baseline) were observed between Day 1 and Week 6 following COMP360 25 mg Part C treatment”
> “Approximately 30% remission rates (Remitter: ≤12 MADRS total score and no single item ≥4) were observed between Day 1 and Week 6 following COMP360 25 mg Part C treatment”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

> “Response/remission rates based on the 142 participants (n=90 from 25mg arm, n=52 from original Placebo arm) who received a 25mg dose in Part C.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Safety summary through Week 26

> “Most TEAEs occurred on the days of study drug administration (66%), with the vast majority (88%) resolving within a day”
> “Most common TEAEs reported were headache, nausea and visual hallucination”
> “There were 11 treatment-emergent serious adverse events (SAEs) from 8 participants (5%) overall”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Common TEAEs included headache, nausea, and visual hallucination, primarily on dosing days and resolving within 24 hours. Eleven SAEs occurred in 8 participants (4.7%).”

Source: [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.8.5-2"></a>

##### Treatment-emergent adverse events in Part A, through Week 6

| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE up to Week 6 | “120 (70.2)” | “34 (39.1)” |
| Any serious TEAE up to Week 6 | “4 (2.3)” | “1 (1.1)” |
| Any TEAE with onset on day of dosing | “118 (69.0)” | “23 (26.4)” |
| Resolved within 1 day | “111 (64.9)” | “22 (25.3)” |
| Resolved after more than 1 and up to 2 days | “15 (8.8)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-3"></a>

##### Treatment-emergent adverse events in Part A with incidence above 5%

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE | “86 (50.3)” | “12 (13.8)” |
| Headache | “42 (24.6)” | “10 (11.5)” |
| Nausea | “35 (20.5)” | “3 (3.4)” |
| Hallucination, visual | “24 (14.0)” | “0” |
| Anxiety | “14 (8.2)” | “2 (2.3)” |
| Dizziness | “10 (5.8)” | “2 (2.3)” |
| Illusion | “9 (5.3)” | “1 (1.1)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-4"></a>

##### Treatment-emergent serious adverse events in Part A

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any SAE | “4 (2.3)” | “1 (1.1)” |
| Suicidal ideation | “2 (1.2)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.1.8.5-5"></a>

##### Treatment-emergent adverse events through Week 26

| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE up to Week 26 | “145 (84.8)” | “52 (59.8)” |
| Any serious TEAE up to Week 26 | “8 (4.7)” | “2 (2.3)” |
| Any TEAE with onset on day of dosing | “121 (70.8” | “25 (28.7)” |
| Resolved within 1 day | “115 (67.3)” | “24 (27.6)” |
| Resolved after more than 1 and up to 2 days | “16 (9.4)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

| MedDRA preferred term (incidence above 10% in the 25 mg arm) | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TEAE | “145 (84.8)” | “52 (59.8)” |
| Headache | “61 (35.7)” | “16 (18.4)” |
| Nausea | “44 (25.7)” | “5 (5.7)” |
| Hallucination, visual | “27 (15.8)” | “0” |
| Anxiety | “22 (12.9)” | “3 (3.4)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Treatment-emergent serious adverse events through Week 26

| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
| --- | --- | --- |
| Any TESAE | “8 (4.7)” | “2 (2.3)” |
| Suicidal ideation | “4 (2.3)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |
| Urinary tract infection bacterial | “0” | “1 (1.1)” |
| Clavicle fracture | “1 (0.6)” | “0” |
| Rib fracture | “1 (0.6)” | “0” |
| Pneumothorax | “1 (0.6)” | “0” |
| Anaphylactic reaction | “1 (0.6)” | “0” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.8.5-7"></a>

##### Suicidality: data safety monitoring board statement, June 2025

> “Based on the latest review of the data for the 005 and 006 studies, safety findings are consistent with previous studies of COMP360 and there are no new or unexpected safety findings. From this review of the data, there is no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

<a id="topic-3.1.1.8.5-8"></a>

##### Suicidality: serious adverse events across COMP005 and COMP006

> “Across both trials, for the data available to date, the rate for SAE suicidal ideation was less than 1%. There was only one event of SAE suicidal behavior, which occurred in the 1 mg arm in COMP006.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.1.8.5-9"></a>

##### Safety in open-label Part C

> “COMP360 safety profile in Part C is consistent with Parts A and B. COMP360 continues to demonstrate a generally well-tolerated and safe profile, with no new safety signals observed.”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data

COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.

Source: [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx); [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm); [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)

<a id="topic-3.1.1.9-2"></a>

#### Company-stated risks of functional unblinding and expectancy bias

> “For example, concerns about functional unblinding, expectancy bias or the impact of our model for supporting and monitoring participants in our clinical trials evaluating COMP360 could hinder interpretability or regulatory acceptability of data from clinical trials of our investigational COMP360 psilocybin treatment.”
> “In addition, our later stage clinical trials may present challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.1.9-3"></a>

#### Regulatory scrutiny of functional unblinding in the phase 3 program

> “In addition, as a result of the increased regulatory scrutiny on functional unblinding, the company has decided to shift the data release for COMP006 until after the 26-week time point and the completion of the blinded portion has been reached for all patients to protect against the risk of unblinding.”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

<a id="topic-3.1.1.9-4"></a>

#### Preliminary topline data not yet reviewed by FDA or published

> “The Company plans to discuss these preliminary COMP005 data with the U.S. Food and Drug Administration (FDA) which has not yet reviewed the data.”

Source: [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)

> “Based on preliminary clinical data that are subject to change as data collection, validation, and analysis continue.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.9-5"></a>

#### Descriptive, observed-case, and post hoc analyses after Week 6

> “No statistical analyses performed after the primary analysis at Week 6”
> “COMP 005 Part B (post Week 6) and COMP 006 Part B (post Week 9) results are based on observed data only (CFB Mean ± 95% CI).”
> “This graph is a post hoc analysis.”
> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.1.9-6"></a>

#### Open-label design of Part C

> “In Part C, open-label from Week 26 to 52, eligible participants from both dosing arms could receive a single dose of 25 mg”
> “Approximately 70% of the study participants continued beyond Week 26 and entered Part C”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-3.1.1.9-7"></a>

#### European Medicines Agency guidance on comparators, expectancy, and unblinding in psychedelic trials

> “Due to the obvious and easily detectable subjective effects induced by an active dose of a psychedelic substance the choice of appropriate comparator while maintaining the blinding can be challenging.”
> “Positive expectancy might lead to overestimation bias while disappointment with treatment (negative expectancy) might lead to symptom worsening or safety issues (nocebo effect).”
> “The use of independent and blinded external raters could help to mitigate the effects of unblinding and expectancy.”
> “Trials need to be able to demonstrate that the effect of the psychedelic assisted therapy is not due to the psychological intervention alone.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.1.9-8"></a>

#### Blinding and expectancy confounds in psychedelic trials

> “We conduct systematic reviews of psychedelic RCTs using Medline, PsychInfo and EMBASE (Jan 1990 - Nov 2020) and show that currently reported psychedelic RCTs have generally not reported pre-trial expectancy, nor the success of blinding procedures.”
> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

> “Of studies with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) used active comparators, 12 (15.0%) used both, and 3 (3.8%) used only different active psychedelic doses as a control.”
> “The majority (81/86; 94%) of studies were blinded, though only 14 (17.3%) included blind assessment; only 8 of these 14 studies assessed participants' blinding. Blinding success, assessed in highly varied ways, was generally poor.”

Source: [Nayak et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37167563/)

> “Blinding integrity may be compromised by perceived treatment efficacy and adverse effects, introducing bias into outcome assessments.”
> “We recommend collecting data on treatment expectations alongside monitoring blinding integrity to more accurately interpret study results.”

Source: [Huneke et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40072447/)

<a id="topic-3.1.1.9-9"></a>

#### Low control-group response in psilocybin depression trials

> “In this meta-analysis of 17 acute-phase randomized clinical trials of psilocybin (n = 373), esketamine (n = 573), or SSRIs (n = 4014), patients receiving control treatments in psilocybin trials had significantly worse depression outcomes compared with those receiving control treatments in trials of esketamine or SSRIs.”
> “Psilocybin in trials for depression has been given in psychedelic doses, which risks making functional unblinding both immediate and prevalent.”
> “Furthermore, since administration is usually supervised, unblinding may also extend to study personnel.”

Source: [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)

<a id="topic-3.1.1.9-10"></a>

#### Comparison with open-label antidepressants under equal unblinding conditions

> “Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions.”
> “Contrary to the first of 3 hypotheses, PAT (8 trials; 249 patients) was no more effective than open-label TAD treatment (16 open-label TAD trials; 7921 patients), with an estimated difference of 0.3 favoring open-label TADs (95% CI, -1.39 to 1.98; P = .73).”

Source: [Williams et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41848744/)

<a id="topic-3.1.1.9-11"></a>

#### Guideline and systematic review assessments of psilocybin trial methods

> “Small sample sizes and functional unblinding were major limitations in all studies.”

Source: [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/)

> “Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.”

Source: [Hovmand et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10350724/)

<a id="topic-3.1.1.9-12"></a>

#### Uncertainty in durability noted in the ICER draft scope

> “The base-case analysis will use a five-year time horizon, reflecting uncertainty in the durability of treatment effects and the limited evidence available to support longer-term extrapolation.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-3.1.1.9-13"></a>

#### Limited long-term evidence on retreatment with psychedelics

> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
